If you’re making a sourcing decision about muscadine, you need to know exactly what the published research shows — not a summary, not a highlight reel. Every study specifically on muscadine relevant to supplement formulation, with design, population, and findings clearly stated.
If you’re a formulator evaluating muscadine as an ingredient, this is your research starting point. Share it with your R&D team. Let your regulatory counsel work from these citations. Build your formula on what the research supports.
Study 1: Banini et al. — Metabolic Markers in T2D Subjects
| Banini AE et al. Nutrition 2006; 22(11–12):1137–1145. North Carolina State University. | |
| Study type | Dietary intervention. Non-randomized. 28 days. |
| Population | Type 2 diabetic subjects (assigned to muscadine juice, wine, or dealcoholized wine) and non-diabetic subjects (juice only) |
| Intervention | 150 mL/day of muscadine grape juice, wine, or dealcoholized wine with meals |
| Key finding | Diabetics given muscadine wine and dealcoholized wine showed lower blood glucose, insulin, and glycated hemoglobin compared to diabetics given juice. Significant improvement in fasting insulin only in the dealcoholized wine group. |
| Limits | Non-diabetic group received juice only — no comparison arm across product types. No placebo control. Beverage forms only — not encapsulated extract. Cannot generalize findings to healthy populations. |
What this gives a formulator: peer-reviewed human research on muscadine and metabolic markers in a population where those markers matter. What it doesn’t give: evidence of metabolic benefit in healthy adults or in capsule supplement form.
Study 2: Mellen et al. — Cardiovascular Markers in Cardiac Risk Population
| Mellen PB et al. J Am Coll Nutr 2010; 29(5):469–475. Hypertension Center of Excellence, Hattiesburg Clinic. | |
| Study type | Randomized, double-blind, placebo-controlled crossover trial. 4 weeks each, 4-week washout. |
| Population | 50 adults with coronary disease or ≥1 cardiac risk factor |
| Intervention | Muscadine grape seed supplement at 1,300 mg/day vs. placebo |
| Key finding | Primary endpoint (FMD): not statistically significant (p=0.06). Secondary finding: significant increase in resting brachial diameter (p=0.002) — clinical significance not yet established. No significant change in inflammation, lipid peroxidation, or antioxidant capacity biomarkers. |
| Limits | Primary endpoint not met. Secondary finding of unclear clinical significance. Authors called for more research. |
What this gives a formulator: one of the most rigorous study designs in nutritional science, applied specifically to muscadine grape seed in a cardiovascular risk population. That research credential is real, even though the primary endpoint wasn’t met. What it doesn’t give: evidence of cardiovascular benefit.
Study 3: Ghanim et al. — Oxidative Stress in a Meal Challenge
| Ghanim H et al. J Clin Endocrinol Metab 2011; 96(5):1409–1414. State University of New York at Buffalo. | |
| Study type | Human meal challenge trial. Randomized crossover with placebo. 10 subjects. |
| Population | 10 healthy adults. High-fat, high-carbohydrate meal challenge. |
| Intervention | Combination supplement containing resveratrol AND muscadine grape polyphenols — not muscadine alone |
| Key finding | The combination supplement reduced meal-induced oxidative and inflammatory stress markers and stimulated Nrf-2 antioxidant transcription factor activity compared to placebo.* |
| Limits | Combination supplement — muscadine’s specific contribution cannot be isolated from resveratrol’s. Small study (n=10). Meal challenge context only, not general supplementation. |
What this gives a formulator: peer-reviewed human evidence that a resveratrol-and-muscadine polyphenol combination affected oxidative stress markers during a meal challenge, including Nrf-2 activation. What it doesn’t give: evidence that muscadine alone produces these effects, or that the same effects occur in a general supplementation context.
Study 4: Patil et al. — Cardiac Damage in an Animal Hypertension Model
| Patil PD et al. Antioxidants 2022; 11(10):2026. Wake Forest University School of Medicine. | |
| Study type | Animal model study. Rodent (Sprague Dawley rats). 4 weeks. |
| Population | Male rats with angiotensin II-induced hypertension |
| Intervention | Muscadine grape skin/seed extract supplement vs. control |
| Key finding | MGES did not affect blood pressure but attenuated hypertension-induced diastolic dysfunction markers (E/e’ ratio) in the animal model. Researchers observed reductions in oxidative stress markers and macrophage infiltration in cardiac tissue. |
| Limits | Animal model only — findings in rats do not directly establish human outcomes. Results are mechanistic and hypothesis-generating, not clinically conclusive. |
What this provides a formulator: peer-reviewed research from Wake Forest University School of Medicine on a muscadine skin/seed extract and cardiovascular-relevant endpoints in an animal model. What it doesn’t provide: human clinical evidence.
What the Full Research File Means for Your Formula
Four published studies specifically on muscadine. Two human trials, one human meal challenge using a combination supplement, and one animal model. That’s a meaningful research base for a botanical ingredient — and we’re presenting every limitation alongside every finding so your team can evaluate them accurately.
Here’s what you can build on, honestly:
- Muscadine has been studied in peer-reviewed human research in metabolic and cardiovascular contexts — areas where formulators face the most scrutiny over ingredient credentials
- The research spans three institutions: North Carolina State University, Hattiesburg Clinic, and Wake Forest University School of Medicine.
- The compound profile studied — skin, seed, juice, and combination forms — maps directly to the ingredient forms MPC supplies.
- No study produced a definitive positive primary outcome in a healthy general population, so your label claims need to be based on structure/function language, with guidance from regulatory counsel
- Your regulatory counsel and R&D team are best positioned to determine how this research base supports your specific formula and claims.
Paulk Vineyards grows muscadines. MPC processes everything on-site. 800+ acres in Wray, Georgia. Seventh generation on the farm, fourth with muscadines. We can provide full documentation for every study cited here.
Request the full research file or a sample at muscadineproducts.com.
| * These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Research references cited include human dietary intervention studies, a human meal-challenge trial using a combination supplement, and an animal model study. Findings from each study reflect what was observed in the specific study population and design described; they do not establish that any MPC muscadine ingredient product produces the same effects. The Ghanim et al. (2011) study used a combination of resveratrol and muscadine polyphenols; muscadine’s independent contribution cannot be isolated from that data. The Patil et al. (2022) study was conducted in an animal model; findings do not directly establish human outcomes. Formulators should consult qualified regulatory counsel before establishing label claims for finished consumer products. Muscadine Products Corporation • Wray, Georgia • muscadineproducts.com |